Higenamine Hydrochloride Ameliorates Diabetic Cardiomyopathy Through RhoA/MEK/ERK Pathway Authors: Ying Li, Lei Wang, Tianyue Guan, Yaru Chen, Wenting Zhu, Xiao Liu, Yusa Li, Hongyu Huang, Zibo Dong, Honggang Zhang Published: 2025 ABSTRACT Diabetic cardiomyopathy (DCM) is a major complication of diabetes, characterized by myocardial inflammation, oxidative stress, fibrosis, apoptosis, and RhoA activation, ultimately leading to heart failure. This study aimed to evaluate whether higenamine hydrochloride (HGN), a natural alkaloid with anti-inflammatory and antioxidant properties, could alleviate DCM and elucidate its underlying mechanisms. A DCM model was established via streptozotocin injection in mice, followed by HGN administration. Fasudil, a RhoA inhibitor, was used to assess pathway involvement. Histology, biochemical assays, flow cytometry, immunoblotting, ELISA, and qPCR were employed for evaluation. Results showed that HGN effectively alleviated cardiac histological abnormalities and myocardial injury in DCM mice. Further analysis revealed that HGN attenuated DCM-induced cardiac inflammation, oxidative stress, fibrosis, and apoptosis (p < 0.05). In vitro, HGN also reduced high glucose-induced inflammation, oxidative stress, fibrosis, and apoptosis in H9C2 cardiomyocytes (p < 0.05). Mechanistically, these protective effects were mediated by inhibition of RhoA, through which HGN suppressed the MEK/ERK signalling pathway, thereby mitigating cardiomyocyte injury (p < 0.05). However, the RhoA inhibitor fasudil hydrochloride abolished the cardioprotective effects of HGN in DCM mice, specifically, fasudil hydrochloride reversed the HGN-induced improvements in cTnT, CK, and LDH levels. Additionally, echocardiographic parameters (IVSD, LVPWd, LVPWs, LVIDd, LVIDs, IVSs, EF, and FS) were also reversed to levels seen in untreated DCM mice, further confirming that HGN exerts its therapeutic actions via the RhoA/MEK/ERK axis (p < 0.05). Overall, HGN mitigates cardiac inflammation, oxidative stress, fibrosis, and apoptosis in DCM by inhibiting the MEK/ERK pathway through RhoA. This study provides a scientific basis for developing DCM treatments and highlights the therapeutic potential of HGN.Graphical Abstract Supplementary InformationThe online version contains supplementary material available at 10.1007/s10753-025-02403-4. Introduction Diabetes could induce DCM, a unique type of cardiomyopathy, characterised by the absence of hypertension, coronary artery disease, and valvular anomalies. This idiopathic condition was potentially life-threatening, with heart failure as its primary clinical outcome [1]. Worldwide, heart diseases were a major health threat, particularly affecting diabetics [2]. Research indicated that DCM significantly contributed to mortality in diabetic populations. Specifically, the all-cause mortality rate in patients with diabetes and DCM was found to be 15.2%, more than double that of DCM patients without diabetes (6.5%) [3]. Given the increasing mortality from DCM, understanding its pathogenesis and developing effective treatments were urgently needed [4]. The pathogenesis of DCM was complex and multifaceted, often initiated by inflammation triggered by hyperglycaemia. This initial inflammation set off a cascade of downstream events, including increased oxidative stress, exacerbated cardiac inflammation, cardiomyocyte apoptosis, accumulation of interstitial fibrosis, and ultimately adverse cardiac remodelling, all of which contributed to the development of heart failure [5]. Effective prevention and treatment of DCM were essential, underscoring the urgent need for potent therapeutic drugs. Hyperglycaemia-induced inflammation was closely linked to DCM. The chronic inflammation associated with diabetes upregulated key pro-inflammatory signalling molecules, including interleukin 6 (IL-6), interleukin 1β (IL-1β), and tumour necrosis factor α (TNF-α) [6]. Elevated blood-sugar levels also stimulated the production of reactive oxygen species (ROS), which activated cellular signalling pathways linked to inflammation, cell apoptosis, and fibrosis. Patients with DCM often exhibited notably higher serum levels of 8-hydroxy-2’-deoxyguanosine (8-OHdG), a biomarker of oxidative stress. This heightened oxidative stress was associated with increased damage to beta cells [7]. Moreover, apoptosis resulting from hyperglycaemia could lead to cardiomyocyte death, thereby worsening cardiac impairment [8]. This showed that apoptosis was essential in driving the progression of DCM and might impact cardiac function through different mechanisms. Therefore, modulating apoptosis might offer new therapeutic strategies for managing DCM. In summary, inflammation, fibrosis, oxidative stress, and apoptosis were pivotal in DCM, yet the regulatory mechanisms governing these phenotypes remained unclear. In DCM, RhoA activation was closely associated with oxidative stress and significantly enhanced ROS production by modulating NADPH oxidase activity. Moreover, RhoA/ROCK pathway activation triggered inflammation, elevating TNF-α and IL-6 levels, which exacerbated myocardial inflammation. By controlling proteins linked to apoptosis, such as Bax and Bcl-2, RhoA activation also encouraged cardiomyocyte apoptosis. Inhibiting the RhoA/ROCK signalling pathway had been reported to effectively enhance cardiomyocyte survival while reducing fibrosis and apoptosis, making it a potential therapeutic target for diabetic cardiomyopathy [9]. Thus, inhibiting RhoA could help mitigate DCM-related inflammation, oxidative stress, fibrosis, and apoptosis. Higenamine hydrochloride (HGN) was a benzylisoquinoline alkaloid that exhibited anti-inflammatory, antioxidant, and cardiovascular protective effects. HGN inhibited the release of inflammatory factors and activated antioxidant enzymes such as HO-1 and SOD, thereby diminishing inflammatory reactions and oxidative stress damage. This dual action not only prevented the activation of myocardial fibroblasts by inflammatory factors, thus inhibiting excessive collagen accumulation and the progression of myocardial fibrosis, but also safeguarded mitochondrial function and suppressed the apoptosis signalling pathway, leading to reduced cardiomyocyte apoptosis [10]. As a result, HGN’s anti-inflammatory and antioxidant properties offered potential protection against myocardial fibrosis and apoptosis. In DCM, myocardial fibrosis and apoptosis were pivotal pathological features [11]. RhoA, a small GTPase, significantly impacted myocardial fibrosis and apoptosis, with its activation driving fibrosis and its inhibition mitigating it [9]. Although no direct evidence currently linked HGN to RhoA inhibition, HGN activated the PI3K/Akt signalling pathway to exert anti-apoptotic and cardiovascular protective effects [12], PI3K/Akt activation could inhibit RhoA [13], supporting the hypothesis of an indirect inhibitory effect of HGN on RhoA. Thus, HGN might positively influence the pathological course of DCM by modulating RhoA activity and reducing myocardial fibrosis. However, the specific therapeutic impact of HGN on DCM remained to be further explored. In this study, we demonstrated that HGN penetrated cardiac tissues and histological abnormalities, myocardial damage, inflammation, oxidative stress, fibrosis, and apoptosis in DCM mice. HGN also prevented high glucose-induced inflammation, oxidative stress, fibrosis, and apoptosis in H9C2 cells by inhibiting the MEK/ERK signalling pathway via RhoA. These protective effects were reversed by RhoA inhibition, highlighting RhoA as a critical mediator of HGN’s therapeutic action. Our findings provided evidence that HGN mitigated DCM-related myocardial injury by targeting RhoA. Materials and Methods Materials Higenamine hydrochloride (HGN, code H413084) and fasudil hydrochloride (F122336) were obtained from Shanghai Aladdin Biochemical Science and Technology Co., Ltd. Streptozotocin (STZ, 18883-66-4) was purchased from McLean Biochemical Science and Technology Co., Ltd., Shanghai, China. The antibodies used in this study included interleukin-6 (IL-6, WL02841), interleukin-1β (IL-1β, WL02257), tumour necrosis factor α (TNF-α, WL01581), Keap1 (WL03285), collagen type I (Collagen-I, WL0088), α-smooth muscle actin (α-SMA, WL02510), transforming growth factor β1 (TGF-β1, WL02193), Bcl-2 (WL01556), and caspase-3 (WL04004) from Shenyang Wanlei Biotechnology Co., Ltd. GPX4 (DF6701) and Nrf2 (AF0639) were sourced from Affinity. The mouse secondary antibody (BA1054) was purchased from Proteintech (Wuhan, China), while caspase-9 (T40046) and GAPDH (P60037S) were obtained from Abmart Biochemical Technology (Shanghai) Co., Ltd. Additional reagents used in this study included sodium citrate buffer (S924872) from McLean Biochemical Technology Co., Ltd., Shanghai, China; insulin (P3376) and sucrose (S818046) from Beyotime; enhanced chemiluminescence (ECL) chemiluminescent solution (E411-04) from Nanjing Novozymes Biotechnology (Vazyme) Co.; and R0010 from Beijing Solarbio Technology Co., Ltd. The Cell Counting Kit-8 (CCK-8) (BS350A) was obtained from Beijing Labgic Science and Technology Co., Ltd. Animal Procurement and Acclimatization Male ICR mice weighing between 20 and 25 g at six weeks of age were purchased from the Yangzhou University Laboratory Animal Center. The mice were acclimatised for seven days before the experiments and were housed in cages lined with bedding that was changed regularly. Environmental humidity was maintained at approximately 55 ± 15%, and temperature was kept at about 25 ± 2 °C. The mice had unrestricted access to food and water to aid their adjustment to their new surroundings. The China Animal Welfare Ethical Review Guidelines and the National Research Council’s Guidelines for the Care and Use of Laboratory Animals were followed in all animal handling and experimental methods. The permission number for all experimental protocols was 20,240,207,002, which was granted by Jiangsu Ocean University’s Laboratory Animal Ethics Committee; this study adhered to the ARRIVE checklist for animal research. Experimental Design and Sample Size To investigate the distribution characteristics of HGN within myocardial tissue, a total of twenty-four experimental mice were included in this part of the study. After injecting 5 mg/kg of HGN into each mouse’s tail vein, blood and cardiac tissues were collected at 5 min, 1 h, 6 h, and 24 h after the injection. Six animals were chosen at random for each time point. To separate the plasma after blood collection, samples were centrifuged at 4,000 × g for 10 min at 4 °C. After homogenising the cardiac tissues at a tissue-to-methanol ratio of 1:3 (g: v), the supernatant was extracted by centrifuging them for 10 min at 4,000 × g. The concentrations of HGN in plasma and heart tissue were measured using LC/MS (Vanquish/TSQ ALTIS, 040411). For the pharmacodynamics and mechanistic investigation of HGN, 48 mice were randomly selected and divided into eight groups: a normal control group (NC), an STZ group, an STZ + HGN (5, 10, 15 mg/kg) group, an STZ + Insulin (RI) group (0.5 IU/kg body weight) [14], an STZ + Fasudil Hydrochloride (60 mg/kg) group [15], and an STZ + Fasudil Hydrochloride + HGN group. The sample size for each group was determined based on preliminary experiments and power analysis to ensure sufficient statistical power to detect significant differences between groups. Inclusion and Exclusion Criteria Inclusion and exclusion criteria were defined as follows. Mice were included in the study if they were six weeks old, weighed between 20 and 25 g, and were free from any visible signs of illness. Mice were excluded if they exhibited signs of distress or illness during the acclimatisation period or if they failed to develop a successful DCM model as determined by fasting blood glucose levels and typical diabetic symptoms. Randomization and Blinding Randomisation and blinding were implemented. Mice were randomly assigned to the different experimental groups. The experimenter was blinded to the group assignments during the experimental procedures and data collection to minimise bias. Induction of DCM Model To establish a mouse model of type I diabetes, preliminary experiments were conducted. The results showed that mice in the STZ group that received 50 mg/kg of STZ via intraperitoneal injection daily for five consecutive days failed to achieve a diabetic model. Therefore, on the sixth day, an additional 100 mg/kg dose of STZ was administered to the mice, and ultimately, all mice developed a type I diabetes model. Based on these preliminary results, the protocol used in the formal experiments was adopted and this method has also been reported in previous studies [16]. Based on these preliminary results, the protocol used in the formal experiments was adopted. Tail vein blood collection was used to evaluate fasting blood glucose levels on day 9. If the DCM mice exhibited typical diabetic symptoms such as polyuria, polydipsia, polyphagia, weight loss, and a fasting blood glucose level of ≥ 11.1 mmol/L [17], it was determined that the DCM modeling had been successful. Treatment and Data Collection From day 10 to day 41, mice in the HGN treatment groups received daily intraperitoneal injections of HGN. From day 28 to day 41, mice in the fasudil hydrochloride group also received daily injections for 14 days [18]. After the treatment period, echocardiography was performed, followed by anaesthesia of the mice with 100 mg/kg body weight of ketamine administered intraperitoneally, blood samples were collected by orbital sampling, and heart tissue was harvested for subsequent analyses. During the administration of HGN, blood glucose levels were monitored, revealing that the 15 mg/kg dose had the most significant effect (Fig. 1A). Consequently, in the STZ + Fasudil Hydrochloride + HGN group, the 15 mg/kg concentration of HGN was selected for testing. The following time planning chart for the experimental design (Fig. 1B) was prepared. Fig. 1A Blood glucose changes in diabetic mice (n = 6). B Experimental design. A Blood glucose changes in diabetic mice (n = 6). B Experimental design. Glucose Measurement and Sample Collection The mice were tested weekly for fasting blood glucose levels. They underwent a fasting period of about 12 h, during which the researchers allowed them to drink freely to maintain their physiology. On the following day, staff collected blood samples from the mice’s tails and measured the fasting blood glucose levels using a glucose-testing device. A painless intraperitoneal injection of anaesthetic was used to end the mice’s lives at the conclusion of the HGN treatment cycle. Following the collection of blood samples, the samples were centrifuged for ten minutes at 4 °C at 4,000 × g. Heart tissues were then removed and washed with 0.9% cold saline to eliminate blood vessels, connective tissues, atria, and the right ventricle. The tissues were then divided in half. One half was frozen and stored for future protein blotting analysis, while the remaining half was preserved for pathological analysis in a 4% neutral buffered formalin solution. Cell Culture H9C2 mouse cardiomyocytes (CRL-1446; BSL 1; ATCC) were carefully maintained in a 37 °C, 5% CO₂ and humidified incubator. The choice of medium was also important, with DMEM as the base medium and the addition of 1% penicillin–streptomycin (PS) and 10% foetal bovine serum (FBS). Together, these conditions created an ideal environment for cell growth. Cell Viability Determination Cell viability was determined using the CCK-8 method, and the optical density (OD) values of the experimental group, the blank group, and the negative control group were read at 450 nm by an enzyme‑labeling instrument. Cell activity was expressed as a percentage of the difference between the OD values of the experimental group and the blank group relative to the difference between the OD values of the negative control group and the blank group. HG Concentration Mapping: H9C2 cells were exposed to varying concentrations of HG medium, with concentrations of 45.5, 85.5, 125.5, 165.5, 205.5, 245.5, 285.5, and 325.5 mM. As a NC group, the glucose concentration was set at 5.5 mM. Cell viability was assessed using the CCK-8 kit after two hours of HG incubation. HGN Safety Concentration Mapping: In this phase, H9C2 cells were exposed to a glucose medium of 5.5 mM combined with HGN concentrations of 0, 0.016, 0.08, 0.4, 2, 10, and 50 µM. The CCK-8 kit was utilised to assess cell viability following a 24-hour incubation period. In Vitro Modeling Based on previous results indicating that a glucose concentration of 165.5 mM damaged H9C2 cells, and the safe concentration range of HGN being 0–2 µM, H9C2 cells in this study were subjected to a 165.5 mM glucose medium with HGN concentrations set at 0.08, 0.4, and 2 µM. The 5.5 mM glucose medium served as the NC group. After 24 h of incubation, both cell viability and inflammation levels were assessed. H&E Staining After removing the experimental mice’s heart tissues, they were promptly cleaned with saline. They were then fixed in a 4% paraformaldehyde solution. The samples were fixed, embedded in paraffin, and dehydrated with ethanol. The tissues were sectioned into slices 4 μm thick, and haematoxylin and eosin (H&E) staining was performed. Using a 20× magnification Olympus BX43 light microscope, the stained slides were examined. Masson Staining Masson trichrome staining was employed to analyse mouse heart tissue in this study. After first removing the mice’s heart tissues and washing them with saline to remove any residual blood or contaminants, the tissues were fixed for 48 h in a 4% paraformaldehyde solution. Then, using a gradient ethanol series (70%, 80%, 90%, 95%, and 100%), the fixed tissues were dehydrated over the course of 15–30 min. Following dehydration, xylene hyalinisation and paraffin embedding were performed on the tissues. A microtome was then used to cut the paraffin-embedded tissues into 5 μm-thick slices, which were placed on slides. Staining was performed according to the Masson Trichrome Staining Kit (Poly Scientific, Bay Shore, NY, USA) instructions: first, Weigert’s iron haemotoxylin staining was used to colour the nuclei black. The collagen fibres were then stained blue with Reichert’s Red (Acidic Complex Red), followed by enhancement with aniline blue. After staining, the tissue sections were mounted with neutral mounting medium and examined at 20× magnification using an Olympus BX43 light microscope. ROS Staining The experimental and NC groups were treated in accordance with the distribution of H9C2 cells into six-well plates until the cell density reached 80%-95%. After washing the cells in the six-well plates with PBS one or two times, the PBS was discarded. After the cells were dissociated with serum-free trypsin, they were collected and placed into 1.5 mL Eppendorf tubes. The cells were centrifuged for 5 min at room temperature at 1,200 × g. The probe solution was prepared by mixing 1 µL of DCFH-DA stock solution with 1 mL serum-free medium, being protected from light. After discarding the previous medium, each tube was filled with 1 mL of the prepared probe solution, the cells were resuspended (ensuring they were not exposed to light), and incubated for 20–30 min. The cells were centrifuged at 1,200 rpm for 5 min at room temperature, after which the supernatant was discarded. Immediately afterwards, these cells were washed with 1 mL of ice-cold PBS, followed by two further centrifugations at 1,200 × g at room temperature, ensuring the entire process was protected from light. Finally, for the purpose of experimental assays, they were transferred to flow cytometer tubes and resuspended in 500 µL of ice-cold PBS. Annexin V-FITC/PI In the H9C2 cell culture system, apoptosis was assessed using the Annexin V-FITC/PI dual-labeling assay. The supernatant of the cell culture fluid was collected first, and then EDTA-free trypsin was used to dissociate the cellular material to obtain the cell suspension; the enzymatically dissociated cells were combined with the previously collected supernatant and then centrifuged for five minutes at 4 °C with 500 × g. To reduce false positives caused by excessive enzymolysis, ice-cold PBS was used to wash the cells twice, and the cells were resuspended after washing. To minimise false positives caused by over-enzymatic digestion, the trypsin exposure time was kept as short as possible. The cells were washed twice with ice-cold PBS, and the centrifugation conditions were 4 °C and 500 × g. After washing, the cells were resuspended in pre-cooled 1× Binding Buffer (concentration range of 1–5 × 10^6 cells/mL), and 100 µL of cell suspension was taken. To this, 5 µL of Annexin V-FITC and 5 µL of PI were added for staining, mixed gently and evenly, and incubated for 8–10 min at room temperature, protected from light. After adding 400 µL of pre-cooled 1 × Binding Buffer, the samples were briefly mixed again. Labeled cells were analysed by fluorescence microscopy or flow cytometry within an hour. Measurement of Cardiac Injury Markers and Physiological and Biochemical Indicators Fresh blood was collected and subsequently stored at 4 °C overnight. To identify indicators of cardiac injury, the investigators performed serum extraction, which was achieved by centrifugation at 5,000 × g for 10 min at 4 °C. The serum was extracted from the blood by centrifugation at 5,000 × g for 10 min. Finally, all enzymes, including CK-MB (creatine kinase isoenzyme), CK (creatine kinase), LDH (lactate dehydrogenase), and cTnT (cardiac troponin), were analysed using an automated biochemical analyser (VITROS V4600, Ortho, USA). The relevant biochemical kits (Isekuju Bio-technology, LLC) were also used to test cardiac tissue homogenates for glutathione (GSH), catalase (CAT), total antioxidant capacity (FRAP), and malondialdehyde (MDA) levels (as a measure of peroxidation) in accordance with the guidelines. Immunoblotting Cardiac tissues were lysed with phenylmethylsulfonyl fluoride (PMSF) in RIPA buffer at 4 °C for 30 min and then centrifuged at 8,000 × g for 10 min at 4 °C. The protein concentration in the supernatant was measured using the BCA method. Electrophoresis was performed on a 12% SDS-polyacrylamide gel at 80 V for 40 min, followed by 120 V for a further 40 min. Proteins were transferred to a PVDF membrane at 200 mA for 90 min. The membrane was blocked with TBST buffer containing 5% skim milk for 2 h to prevent non-specific binding. After blocking, the membrane was briefly washed with TBST buffer. Subsequently, the membrane was incubated overnight at 4 °C with a specific primary antibody targeting the target protein. This overnight incubation allowed the primary antibody to bind specifically to the target protein on the membrane. After incubation with the primary antibody, the membrane was washed three times with TBST buffer for 10 min each time to remove unbound primary antibody. Subsequently, the membrane was incubated with horseradish peroxidase-labeled secondary antibody at room temperature for 60 min. Protein bands were visualised with ECL solution, imaged, and quantified using ImageJ software. Quantitative Real-Time Fluorescence PCR To extract RNA, 500 µL of Trizol reagent was added to 20 mg of crushed heart tissue. H9C2 cells were taken from a six-well plate, rinsed with PBS, pipetted into a 1.5 mL Eppendorf tube, and then combined with Trizol reagent. Two hundred microlitres of ice-cold chloroform were then added, and the mixture was thoroughly agitated to separate the aqueous and organic phases. Five hundred microlitres of isopropanol were added to the mixture after it had stood to precipitate the RNA. After precipitation, the RNA was rinsed with 75% ethanol, allowed to air dry, and then dissolved in RNase-free water. To gauge the purity and quantity of the RNA, a NanoDrop spectrophotometer was used. For cDNA synthesis, 1 µg of RNA was reverse-transcribed using the Vazyme cDNA Synthesis Kit (Vazyme, R223-01; 100 rxns) following the manufacturer’s protocol. The subsequent step involved a qPCR (quantitative polymerase chain reaction) on a machine, using SYBR Green from Monad, Wuhan, China, with β-actin as a control. The expression levels of the mRNA were then evaluated using the 2−ΔΔCt method [19–21]. We purchased primers for the target genes (Table 1) from Sangon Biotech in Shanghai, China. Table 1Specific primer sequences for analyzed genesGeneForward (5′-3′)Reverse (5′-3′) tnf-α CAGAAACCCTGGACTGGAAACCTGGCTGTAGACGAAGTAAAT il-6 GGACGACAGAGCTCTTAGAAACGGCCAGAGACTGTTGATACTG il-1β TCCAAGCACGTCGTGTGACTGACGAGGAGATCCGCTGCTT tgf-β1 AGTGCTTTTGCATACCTGCATGCTTGCTCCGAACTTGCTTG collagen I GATTCCCTGGACCTAAAGGTGCAGCCTCTCCATCTTTGCCAGCA α-sma AGACATCAGGGTGTAGTGGTGGCATGGCTGGGACATTGAAAGG bcl-2 CTGGATGACAGACTACCTGAACTACGACAATGGGTGGAACATAG caspase3 TGACCAGGGTCAACCATAAAGTGGTGAGCATCGAGACAATG caspase9 GATGACCAGATGGACGCTATTCGACGTATCCTGGAAAGGTTGAG nrf2 GAACTGCCTCCTCTGACTATTGACGGCCTGTGGAATACTTTAG keap-1 TCTATGTGATGGGAGGATACGAGTGTCTCATGGAGGAGATGAAG gpx4 GAGGCAAGACCGAAGTAAACTACCCGAACTGGTTACACGGGAA β-actin CCTTCCAGCAGATGTGGATTAGTGAAGTGGTAACAGTCCGTTTAG Table 1Specific primer sequences for analyzed genesGeneForward (5′-3′)Reverse (5′-3′) tnf-α CAGAAACCCTGGACTGGAAACCTGGCTGTAGACGAAGTAAAT il-6 GGACGACAGAGCTCTTAGAAACGGCCAGAGACTGTTGATACTG il-1β TCCAAGCACGTCGTGTGACTGACGAGGAGATCCGCTGCTT tgf-β1 AGTGCTTTTGCATACCTGCATGCTTGCTCCGAACTTGCTTG collagen I GATTCCCTGGACCTAAAGGTGCAGCCTCTCCATCTTTGCCAGCA α-sma AGACATCAGGGTGTAGTGGTGGCATGGCTGGGACATTGAAAGG bcl-2 CTGGATGACAGACTACCTGAACTACGACAATGGGTGGAACATAG caspase3 TGACCAGGGTCAACCATAAAGTGGTGAGCATCGAGACAATG caspase9 GATGACCAGATGGACGCTATTCGACGTATCCTGGAAAGGTTGAG nrf2 GAACTGCCTCCTCTGACTATTGACGGCCTGTGGAATACTTTAG keap-1 TCTATGTGATGGGAGGATACGAGTGTCTCATGGAGGAGATGAAG gpx4 GAGGCAAGACCGAAGTAAACTACCCGAACTGGTTACACGGGAA β-actin CCTTCCAGCAGATGTGGATTAGTGAAGTGGTAACAGTCCGTTTAG Specific primer sequences for analyzed genes Echocardiographic Assessment After the experimental period had finished, mice were evaluated using echocardiography with a Feyno VINNO 6 LAB portable digital diagnostic ultrasound machine (model: VINNO 6 LAB, YX094). As previously mentioned [22], several structural parameters were assessed, including systolic left ventricular posterior wall thickness (LVPWs), diastolic left ventricular internal dimension (LVIDd), systolic left ventricular internal dimension (LVIDs), systolic interventricular septal thickness (IVSs), diastolic interventricular septal thickness (IVSd), and diastolic left ventricular posterior wall thickness (LVPWd). Additionally, fractional shortening (FS) and ejection fraction (EF) were employed to evaluate left ventricular (LV) function. Cell Transfection A RhoA overexpression plasmid was created to examine the impact of RhoA overexpression on cellular function (P43016, Wuhan Miao Ling Plasmid Platform). The plasmid was added to LB liquid medium and shaken for 8–12 h. DNA was then extracted using an endotoxin-free plasmid extraction kit, and the concentration was measured with a NanoDrop microspectrophotometer. For the transfection experiments, cells in good condition were seeded at 80% confluence in six-well plates. In a sterile centrifuge tube, 6 µL of ExFect transfection reagent (T101-01, Vazyme) and 3 µg of plasmid DNA were added to Opti-MEM medium and gently mixed to form the ExFect/DNA complex. The complex was incubated for 15–20 min at room temperature. Cells were resuspended with serum-free medium after being washed with PBS to remove antibiotics prior to transfection. The ExFect/DNA complex was then added dropwise to the medium, and the dish was gently agitated to ensure uniform distribution. The medium was replaced with maintenance medium four to six hours after transfection. The expression of RhoA protein was assessed by immunoblotting 24–48 h post-transfection to confirm transfection efficiency. Statistical Analysis Data are presented as mean ± standard deviation (SD). Normality was assessed using the Shapiro–Wilk test, and homogeneity of variances was assessed using Levene’s test. Because both assumptions were met, one-way ANOVA was performed in GraphPad Prism (v8.0, GraphPad Software, San Diego, CA, USA). Tukey’s honestly significant difference test was used for post hoc multiple comparisons among all groups. A p value < 0.05 was considered statistically significant. The above statistical methods apply to the analysis of all bar-graph results presented in this manuscript. Results HGN Distribution in Cardiac Tissue The entry of HGN into the cardiac tissue of DCM mice was a prerequisite for its therapeutic effect. To investigate whether HGN could penetrate cardiac tissue and exert therapeutic benefits, we conducted cardiac tissue distribution experiments (Fig. 2A). Mice received intravenous injections of 5 mg/kg of HGN in the tail vein, and the drug concentration-time profiles were recorded and analysed following administration. The results demonstrated that the concentration of HGN reached a maximum in cardiac tissue and plasma within 5 min, followed by a rapid decline (Fig. 2B). These findings indicated that HGN could effectively enter cardiac tissues, which was a necessary step for its potential therapeutic effects. Fig. 2HGN distribution in cardiac tissue. A Flow chart of the experiment. B Concentrations of HGN in mouse heart and plasma (n = 6) HGN distribution in cardiac tissue. A Flow chart of the experiment. B Concentrations of HGN in mouse heart and plasma (n = 6) HGN Alleviates Cardiac Histologic Abnormalities in DCM Mice Histological abnormalities in the hearts of DCM mice were primarily characterised by inflammatory cell infiltration and myocardial fibrosis [23]. The impact of HGN on DCM mice’s heart tissues was evaluated through the use of haematoxylin and eosin (H&E) and Masson’s trichrome staining. HE staining revealed that, relative to the NC group, DCM mice showed cardiac hypertrophy and disorganised cardiomyocyte arrangement, myofibrillar fracture and lysis, along with interstitial inflammatory cell infiltration, vacuolisation, and granulation tissue formation in microvessels (Fig. 3A). Notably, myocardial morphology improved in DCM mice after administration of various concentrations of HGN. Masson staining results (Fig. 3B) further revealed that the myocytes in DCM mice were disorganised and exhibited increased collagen fibres and significant fibrosis when compared to the NC group, whereas myocardial fibrosis was reduced following HGN treatment. Oxidative stress played a pivotal role in the development of DCM, leading to cardiomyocyte injury through multiple pathways [24]. To explore the impact of oxidative stress, we employed oxidative stress-related assays. According to the results (Fig. 3C-F), DCM mice exhibited lower levels of GSH, SOD, and FRAP, whereas MDA levels were higher. These results suggested that oxidative stress was exacerbated, antioxidant capacity was diminished, and overall antioxidant defence mechanisms were impaired in DCM mice. In contrast, HGN administration resulted in reductions in MDA levels and increases in SOD, GSH, and FRAP levels, indicating that HGN may have a beneficial effect on mitigating oxidative stress and improving antioxidant status. In our in vitro modelling, we found that HG at a concentration of 165.5 mM caused significant damage to the cells, while HGN at a concentration of 2 µM did not adversely affect cell viability. Consequently, we selected 165.5 mM as the concentration for constructing the in vitro H9C2 cell model for DCM and 2 µM as the optimal concentration for HGN activity (Fig. 3H-J). Additionally, our evaluation revealed higher ROS levels in the HG group compared with the NC group. However, as varying dosages of HGN were administered, ROS levels gradually declined (Fig. 3G). Furthermore, the HG group exhibited a considerably higher number of apoptotic cells than the NC group, according to FITC-PI double labeling (Fig. 3K). By contrast, HGN therapy decreased the apoptotic cell number in the HG group. These findings suggested that HGN may have inhibited cardiac inflammation, oxidative stress, fibrosis, and apoptosis. Therefore, HGN appeared to have had a beneficial effect on alleviating cardiac histological abnormalities in DCM mice. Fig. 3Effects of HGN on histologic abnormalities in the heart of DCM mice. A HE staining: Red arrows (hypertrophy), blue arrows (myofibril breakage), green arrows (inflammatory infiltration), yellow arrows (vacuolization), white arrows (granulation tissue). B Masson staining: Yellow arrows (disorganized arrangement), green arrows (collagen fibers). C-F Biochemical analysis: MDA, SOD, GSH, FRAP (n = 6). G Flow cytometry: ROS. H-J CCK8 assays: HG (n = 3), HGN (n = 3), HG + HGN (n = 3). K Apoptotic cardiomyocytes: FITC-PI double-staining. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) Effects of HGN on histologic abnormalities in the heart of DCM mice. A HE staining: Red arrows (hypertrophy), blue arrows (myofibril breakage), green arrows (inflammatory infiltration), yellow arrows (vacuolization), white arrows (granulation tissue). B Masson staining: Yellow arrows (disorganized arrangement), green arrows (collagen fibers). C-F Biochemical analysis: MDA, SOD, GSH, FRAP (n = 6). G Flow cytometry: ROS. H-J CCK8 assays: HG (n = 3), HGN (n = 3), HG + HGN (n = 3). K Apoptotic cardiomyocytes: FITC-PI double-staining. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) HGN Alleviates Myocardial Injury in DCM Mice Myocardial oxidative stress and inflammatory responses triggered by diabetes were key factors contributing to myocardial injury [25]– [26]. We investigated HGN’s possible protective benefits against myocardial injury in DCM mice further after our initial results showed that it efficiently lowered cardiac inflammation and oxidative stress caused by DCM. In this investigation, we measured blood levels of cTnT, CK, and LDH to evaluate myocardial injury, as well as by assessing ventricular hypertrophy in DCM mice. Elevated levels of cTnT, CK, and LDH in serum were typically associated with myocardial injury. The results demonstrated that the hearts of DCM mice exhibited hypertrophy compared with the NC group (Fig. 4A). Notably, cardiac hypertrophy was significantly reduced in DCM mice following treatment with various doses of HGN, suggesting that HGN had an inhibitory effect on cardiac hypertrophy. Furthermore, DCM animals had significantly greater serum levels of cTnT, CK, and LDH than the NC group, indicating serious myocardial damage (Fig. 4B-D). On the other hand, HGN decreased the blood concentrations of cTnT, CK, and LDH in DCM mice following treatment, indicating that HGN had the potential to mitigate myocardial injury. Overall, the study’s findings suggested that HGN treatment was associated with reductions in myocardial damage markers in DCM mice. Fig. 4Effect of HGN on myocardial injury in DCM mice. A Cardiac histograms of diabetic mice (n = 6). B-D Serum levels of cTnT, CK, and LDH (n = 6). Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) vs. STZ group Effect of HGN on myocardial injury in DCM mice. A Cardiac histograms of diabetic mice (n = 6). B-D Serum levels of cTnT, CK, and LDH (n = 6). Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) vs. STZ group HGN Attenuates DCM-induced Cardiac inflammation, Oxidative stress, Fibrosis and Apoptosis DCM-induced myocardial damage was intimately related to oxidative stress, fibrosis, apoptosis, and cardiac inflammation; these pathological processes interacted to promote the formation of cardiac lesions [23]. Taking these factors into account, we investigated how HGN affected DCM-induced cardiac inflammation, oxidative stress, fibrosis, and apoptosis. We also employed immunoblotting assays to evaluate the expression of relevant proteins. The results showed that DCM mice had considerably greater levels of the inflammatory proteins IL-6, TNF-α, and IL-1β than the NC group (Fig. 5A-D). Pro-oxidative stress-related protein Keap1 levels were also significantly increased, while antioxidant-related proteins GPX4 and NRF2 showed decreased expression (Fig. 5E-H). Furthermore, fibrosis-related proteins TGF-β1, α-SMA, and Collagen I exhibited markedly increased expression levels (Fig. 5I-L). Pro-apoptotic proteins Caspase-3, Procaspase-9, and Cleaved caspase-9 were significantly upregulated while the anti-apoptotic protein BCL2 was downregulated (Fig. 5M-Q). Following treatment with HGN at varying dosages, there was a marked decrease in the expression of the inflammatory proteins IL-6, TNF-α, and IL-1β. The level of pro-oxidative stress-related protein Keap1 was considerably lower, whereas the level of antioxidant-related proteins GPX4 and NRF2 increased. Collagen I, α-SMA, and TGF-β1, which are proteins linked to fibrosis, were also markedly reduced. In addition, there was a considerable decrease in the expression of the pro-apoptotic proteins Caspase-3, Pro-Caspase-9, and Cleaved Caspase-9, and an increase in the expression of the anti-apoptotic protein BCL2. These results suggested that HGN might have had a beneficial impact on reducing myocardial inflammation, oxidative stress, fibrosis, and apoptosis in DCM mice. Fig. 5Effects of HGN on DCM-induced cardiac inflammation, oxidative stress, fibrosis, and apoptosis. A Immunoblotting for IL-6, TNF-α, IL-1β (GAPDH as reference, n = 6). B-D Quantification of IL-6, TNF-α, IL-1β. E Immunoblotting for GPX4, Keap1, NRF2 (GAPDH as control, n = 6). F-H Quantification of GPX4, Keap1, NRF2. I Immunoblotting for TGF-β1, α-SMA, Collagen I (GAPDH as control, n = 6). J-L Quantification of TGF-β1, α-SMA, Collagen I. M Immunoblotting for BCL2, Caspase-3, Pro Caspase-9, Cleaved Caspase-9 (GAPDH as control, n = 6). N-Q Quantification of BCL2, Caspase-3, Pro Caspase-9, Cleaved Caspase-9. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) vs. STZ group Effects of HGN on DCM-induced cardiac inflammation, oxidative stress, fibrosis, and apoptosis. A Immunoblotting for IL-6, TNF-α, IL-1β (GAPDH as reference, n = 6). B-D Quantification of IL-6, TNF-α, IL-1β. E Immunoblotting for GPX4, Keap1, NRF2 (GAPDH as control, n = 6). F-H Quantification of GPX4, Keap1, NRF2. I Immunoblotting for TGF-β1, α-SMA, Collagen I (GAPDH as control, n = 6). J-L Quantification of TGF-β1, α-SMA, Collagen I. M Immunoblotting for BCL2, Caspase-3, Pro Caspase-9, Cleaved Caspase-9 (GAPDH as control, n = 6). N-Q Quantification of BCL2, Caspase-3, Pro Caspase-9, Cleaved Caspase-9. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) vs. STZ group HGN Alleviates HG-induced inflammation, Oxidative stress, Fibrosis and Apoptosis in H9C2 Cells H9C2 cells were frequently employed as models to investigate oxidative stress, fibrosis, apoptosis, inflammation, and cardiomyocyte damage. Building on the in vivo results, we further investigated the impacts of HGN on H9C2 cells via in vitro experiments. tnfa mRNA and the inflammation-related proteins IL-6 and IL-1β were present at significantly higher levels in the HG-treated group compared to the NC group, according to immunoblotting and real-time fluorescence quantitative PCR data (Fig. 6A-D). In contrast, the pro-oxidative stress protein Keap1 had considerably higher expression than the antioxidant-related proteins GPX4 and NRF2 (Fig. 6E-H). Collagen I, α-SMA, and TGF-β1, which were proteins linked to fibrosis, were also markedly increased (Fig. 6I-L). The pro-apoptotic proteins Caspase-3, Procaspase-9, and Cleaved Caspase-9 were significantly elevated, while the anti-apoptotic protein BCL2 was significantly reduced (Fig. 6M-Q). Following HGN administration, a notable decrease was seen in the expression of tnfα mRNA and the inflammatory proteins IL-6 and IL-1β, with protein levels of IL-6 and IL-1β decreasing by approximately 50–60%. The levels of the pro-oxidative stress protein Keap1 were dramatically reduced, but the degree of the antioxidant-related proteins GPX4 and NRF2 were significantly raised, with GPX4 protein levels nearly doubling. The expression of proteins linked to fibrosis, such as TGF-β1, α-SMA, and collagen I, was also markedly reduced. Furthermore, anti-apoptotic protein BCL2 levels rose markedly, while the levels of the pro-apoptotic proteins Caspase-3, Procaspase-9, and Cleaved Caspase-9 decreased. In summary, HGN treatment was associated with reductions in inflammation, oxidative stress, fibrosis, and apoptosis in HG-induced H9C2 cells. Fig. 6Effect of HGN on HG-induced inflammation, oxidative stress, fibrosis and apoptosis in H9C2 cells. A Immunoblotting for IL-6, IL-1β (GAPDH as reference, n = 6). B-D Quantification of IL-6, IL-1β, tnf-α mRNA. E Immunoblotting for GPX4, NRF2, Keap1 (GAPDH as control, n = 6). F-H Quantification of GPX4, NRF2, Keap1. I Immunoblotting for TGF-β1, α-SMA, Collagen I (GAPDH as control, n = 6). J-L Quantification of TGF-β1, α-SMA, Collagen I. M Immunoblotting for BCL2, Caspase-3, Pro-caspase-9, Cleaved caspase-9 (GAPDH as control, n = 6). N-Q Quantification of BCL2, Caspase-3, Pro-caspase-9, Cleaved caspase-9. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) vs. STZ group Effect of HGN on HG-induced inflammation, oxidative stress, fibrosis and apoptosis in H9C2 cells. A Immunoblotting for IL-6, IL-1β (GAPDH as reference, n = 6). B-D Quantification of IL-6, IL-1β, tnf-α mRNA. E Immunoblotting for GPX4, NRF2, Keap1 (GAPDH as control, n = 6). F-H Quantification of GPX4, NRF2, Keap1. I Immunoblotting for TGF-β1, α-SMA, Collagen I (GAPDH as control, n = 6). J-L Quantification of TGF-β1, α-SMA, Collagen I. M Immunoblotting for BCL2, Caspase-3, Pro-caspase-9, Cleaved caspase-9 (GAPDH as control, n = 6). N-Q Quantification of BCL2, Caspase-3, Pro-caspase-9, Cleaved caspase-9. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) vs. STZ group HGN Inhibits inflammation, Oxidative stress, Fibrosis and Apoptosis in H9C2 Cells Via RhoA Prior studies have shown that inhibiting RhoA effectively controls oxidative stress, fibrosis, apoptosis, and inflammation [13, 27]. This study therefore sought to determine whether HGN could inhibit RhoA in H9C2 cells treated with HG and whether this inhibition might reduce oxidative stress, inflammation, fibrosis, and apoptosis through RhoA targeting. Immunoblotting assays revealed a notable uptick in RhoA protein expression within the HG group as compared to the NC group (Fig. 7A, B). Moreover, there was a concurrent and marked surge in the inflammatory cytokines IL-6, TNF-α, and IL-1β (Fig. 7C-F). The level of the pro-oxidative stress protein Keap1 rose significantly, whereas the expression of the anti-oxidative stress proteins GPX4 and NRF2 decreased notably (Fig. 7G-J). Also markedly increased were the pro-fibrotic proteins TGF-β1, α-SMA, and Collagen I (Fig. 7K-N). Caspase-3 and Procaspase-9 levels were notably increased, as was active Caspase-9, whereas the apoptosis-suppressing protein BCL2 experienced a marked reduction (Fig. 7O-S). Compared with the HG group, the HG + HGN group’s RhoA protein expression was much lower. The expression of the pro-oxidative stress protein Keap1 and the inflammatory proteins IL-6, TNF-α, and IL-1β was significantly reduced. Conversely, the antioxidant proteins GPX4 and NRF2 exhibited markedly greater expression. The pro-fibrotic proteins TGF-β1, α-SMA, and collagen I were all expressed at lower levels. The pro-apoptotic proteins Caspase-3, Procaspase-9, and Cleaved caspase-9 showed significantly lower levels of protein expression, while the anti-apoptotic protein BCL2 showed significantly higher levels. The HG + RhoAOE group exhibited significantly higher levels of protein expression of RhoA, IL-6, TNF-α, IL-1β, Keap1, TGF-β1, α-SMA, Collagen I, Caspase-3, Procaspase-9, and Cleaved caspase-9 than the HG group. In contrast, there was a considerable downregulation of the protein expression of BCL2, NRF2, and GPX4. However, once again, the expression levels of these proteins showed an opposite trend in the HG + RhoAOE+HGN group compared to the HG + HGN group. There was a significantly higher expression of pro-inflammatory factors, pro-oxidative stress-related proteins, pro-fibrotic markers, and pro-apoptotic proteins, while the expression of antioxidant proteins and anti-apoptotic proteins was significantly lower. According to these results, HGN may have targeted RhoA and may have had a protective effect against HG-induced apoptosis, fibrosis, oxidative stress, and inflammation in H9C2 cells. Fig. 7Effect of HGN on RhoA inhibition of inflammation, oxidative stress, fibrosis and apoptosis in H9C2 cells. A Immunoblotting for RhoA (GAPDH as reference, n = 6). B Quantification of RhoA. C Immunoblotting for IL−6, TNF-α, IL−1β (GAPDH as reference, n = 6). D-F Quantification of IL−6, TNF-α, IL−1β. G Immunoblotting for GPX4, NRF2, Keap1 (GAPDH as control, n = 6). H-J Quantification of GPX4, NRF2, Keap1. K Immunoblotting for TGF-β1, α-SMA, Collagen I (GAPDH as control, n = 6). L-N Quantification of TGF-β1, α-SMA, Collagen I. O Immunoblotting for BCL2, Pro-Caspase−3, Cleaved Caspase−3, Pro-Caspase−9, Cleaved Caspase−9, RhoA (GAPDH as control, n = 6). P-S Quantification of BCL2, Pro-Caspase−3, Cleaved Caspase−3, Pro-Caspase−9, Cleaved Caspase−9. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) vs. STZ group Effect of HGN on RhoA inhibition of inflammation, oxidative stress, fibrosis and apoptosis in H9C2 cells. A Immunoblotting for RhoA (GAPDH as reference, n = 6). B Quantification of RhoA. C Immunoblotting for IL−6, TNF-α, IL−1β (GAPDH as reference, n = 6). D-F Quantification of IL−6, TNF-α, IL−1β. G Immunoblotting for GPX4, NRF2, Keap1 (GAPDH as control, n = 6). H-J Quantification of GPX4, NRF2, Keap1. K Immunoblotting for TGF-β1, α-SMA, Collagen I (GAPDH as control, n = 6). L-N Quantification of TGF-β1, α-SMA, Collagen I. O Immunoblotting for BCL2, Pro-Caspase−3, Cleaved Caspase−3, Pro-Caspase−9, Cleaved Caspase−9, RhoA (GAPDH as control, n = 6). P-S Quantification of BCL2, Pro-Caspase−3, Cleaved Caspase−3, Pro-Caspase−9, Cleaved Caspase−9. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) vs. STZ group HGN Inhibits Cardiomyocyte inflammation, Oxidative stress, Fibrosis and Apoptosis Through RhoA Inhibition of MEK/ERK It has been discovered that when the MEK/ERK signaling pathway is active, DCM increases inflammation, oxidative stress, fibrosis, and apoptosis [28]. It remained unclear whether HGN could reduce inflammation, oxidative stress, fibrosis, and apoptosis in HG-induced H9C2 cells by inhibiting the MEK/ERK signalling cascade via RhoA. The findings of the experiment showed that the HG group had considerably greater levels of protein expression of p-MEK1/2 and p-ERK1/2 than the NC group (Fig. 8A-C). However, in contrast to the HG group, the HG + HGN group had considerably reduced levels of p-MEK1/2 and p-ERK1/2 expression. In contrast, there was a considerable rise in p-MEK1/2 and p-ERK1/2 expression levels in the HG + RhoAOE group. Additionally, p-MEK1/2 and p-ERK1/2 protein levels were noticeably higher in the HG + RhoAOE+HGN group than in the HG + HGN group. These results suggest that HGN may reduce inflammation, oxidative stress, fibrosis, and cell death in cardiomyocytes, potentially via modulation of the MEK/ERK signaling cascade through RhoA. Fig. 8Effect of HGN on RhoA inhibition of MEK/ERK to suppress the expression of inflammation, oxidative stress, fibrosis, and apoptosis-related cytokines in cardiomyocytes. A Immunoblotting for p-MEK1/2 and p-ERK1/2, normalized to GAPDH (n = 6). B-C Quantitative analysis of p-MEK1/2 and p-ERK1/2. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) Effect of HGN on RhoA inhibition of MEK/ERK to suppress the expression of inflammation, oxidative stress, fibrosis, and apoptosis-related cytokines in cardiomyocytes. A Immunoblotting for p-MEK1/2 and p-ERK1/2, normalized to GAPDH (n = 6). B-C Quantitative analysis of p-MEK1/2 and p-ERK1/2. Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) Fasudil Hydrochloride Eliminates the Protective Effect of HGN against Myocardial Injury in DCM Mice Studies conducted in vitro had shown that HGN decreased RhoA expression, which possessed an anti-DCM effect. We had performed tests in a DCM mouse model to confirm this finding. To assess the impact of HGN on myocardial damage, we had used the RhoA inhibitor fasudil hydrochloride [29], which included assessments of LV dimensions and function as well as serum-related parameters. The STZ + HGN group exhibited considerably lower levels of cTnT, CK, and LDH than the DCM animals, according to our ELISA data (Fig. 9A-C). However, there were no appreciable variations in the levels of cTnT, CK, or LDH between the DCM mice and the STZ + fasudil hydrochloride group. Furthermore, cTnT, CK, and LDH levels were noticeably greater in the STZ + fasudil hydrochloride + HGN group than in the STZ + HGN group, which suggested that fasudil hydrochloride may have counteracted some of the protective effects of HGN. These results indicated that HGN exerted its protective effects through the RhoA/MEK/ERK pathway. The STZ + HGN group had notably decreased measurements of IVSD, LVPWd, LVIDs, LVIDd, and IVSs compared with the DCM mice, according to echocardiographic evaluations (Fig. 9D-L). On the other hand, the STZ + HGN group’s left ventricular EF and FS were noticeably higher. This indicated recovery of impaired cardiac function, as evidenced by decreased thickness of the posterior wall and interventricular septum, reduced left ventricular dilatation, and improved ventricular contractility. In contrast, the STZ + fasudil hydrochloride group did not exhibit any appreciable variations in IVSD, LVPWd, LVPWs, LVIDd, LVIDs, IVSs, EF, and FS when compared with the DCM mice. Furthermore, the STZ + fasudil hydrochloride + HGN group had significantly lower EF and FS and significantly greater levels of IVSD, LVPWd, LVPWs, LVIDd, LVIDs, and IVSs than the STZ + HGN group. In summary, fasudil hydrochloride appeared to counteract the cardioprotective effect of HGN in DCM murine myocardial injury. Fig. 9Effect of Fasudil Hydrochloride on myocardial injury of HGN in DCM mice. A-C Serum levels of cTnT, CK, and LDH (n = 6). D-L Echocardiographic parameters: IVSD, LVPWd, LVPWs, LVIDd, LVIDs, IVSs, EF, FS (n = 6). Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001) Effect of Fasudil Hydrochloride on myocardial injury of HGN in DCM mice. A-C Serum levels of cTnT, CK, and LDH (n = 6). D-L Echocardiographic parameters: IVSD, LVPWd, LVPWs, LVIDd, LVIDs, IVSs, EF, FS (n = 6). Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001) Fasudil Hydrochloride Eliminates the Therapeutic Effects of HGN on Cardiac Inflammation, Oxidative Stress, Fibrosis, and Apoptosis in DCM Mice Since the inhibitory target, RhoA, had been essential for controlling oxidative stress, inflammation, fibrosis, and apoptosis, we investigated whether HGN acted via RhoA. As demonstrated by the downregulation of il-6, tnfa, and il-β mRNA expression, real-time fluorescence quantitative PCR results demonstrated that HGN treatment dramatically decreased the expression levels of inflammation-related mRNAs compared with DCM animals (Fig. 10A-C). Furthermore, there were notable changes in the levels of mRNA expression linked to oxidative stress: gpx4 and nrf2 mRNA levels rose, but keap1 mRNA expression fell (Fig. 10D-F). Moreover, the expression levels of fibrosis-related mRNAs were also significantly decreased, as shown by a notable down-regulation of the mRNA amounts of tgfβ1, α-sma, and collagen I (Fig. 10G-I). bcl2 mRNA expression dramatically increased in relation to apoptosis-related markers, but caspase-3 and caspase-9 mRNA expression declined (Fig. 10J-L). When compared with DCM mice, the mRNA expression levels of inflammation-related markers (il-6, tnfa, il-β), oxidative stress-related markers (keap1, gpx4, nrf2), fibrosis-related markers (tgfβ1, α-sma, collagen I), and apoptosis-related markers (caspase-3, caspase-9, and bcl2) did not show any significant disparities in their mRNA expression levels. Notably, the STZ + Fasudil Hydrochloride + HGN group exhibited a large rise in Keap1 and demonstrated significantly greater expression of inflammation-related markers ((il-6, tnfa and il-β) compared with the STZ + HGN group. In contrast, GPX4 and NRF2 expression dropped, whereas fibrosis-related factors (such as tgfβ1, α-sma, and collagen I) rose. Moreover, the levels of caspase-3 and caspase-9 rose while that of bcl2 declined. In conclusion, Fasudil Hydrochloride appeared to attenuate the therapeutic effects of HGN on oxidative stress, fibrosis, apoptosis, and cardiac inflammation in DCM mice. Fig. 10Effects of Fasudil Hydrochloride on inflammation, oxidative stress, fibrosis and apoptosis in the heart of DCM mice by HGN. A-C mRNA levels of inflammation-related factors (il-6, tnfa, il-β) in mouse cardiac tissues (n = 6). D-F mRNA levels of oxidative stress-related factors (gpx4, keap1, nrf2) (n = 6). G-I mRNA levels of fibrosis-related factors (tgfβ1, a-sma, collagen I) (n = 6). J-L mRNA levels of apoptosis-related factors (bcl2, caspase-3, caspase-9) (n = 6). Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) Effects of Fasudil Hydrochloride on inflammation, oxidative stress, fibrosis and apoptosis in the heart of DCM mice by HGN. A-C mRNA levels of inflammation-related factors (il-6, tnfa, il-β) in mouse cardiac tissues (n = 6). D-F mRNA levels of oxidative stress-related factors (gpx4, keap1, nrf2) (n = 6). G-I mRNA levels of fibrosis-related factors (tgfβ1, a-sma, collagen I) (n = 6). J-L mRNA levels of apoptosis-related factors (bcl2, caspase-3, caspase-9) (n = 6). Significance: ns (p > 0.05), * (p < 0.05), ** (p < 0.01), *** (p < 0.001), **** (p < 0.0001) Discussion Diabetes mellitus was considered the epidemic of the 21st century and was closely linked to multiple organ damage. Among these complications, cardiovascular issues led to significant mortality and disease burden in Western countries. Therefore, understanding the pathomechanisms of cardiovascular complications in diabetic patients was essential for developing new therapeutic strategies [30]. Although some studies had demonstrated that HGN had a protective effect against cardiovascular disease [31], its protective role in DCM remained unexplored. In this research, we developed a mouse model of DCM to investigate the therapeutic potential of HGN. Our results demonstrated that HGN significantly mitigated cardiac histological abnormalities and myocardial injury in DCM mice. Furthermore, in these mice, HGN decreased oxidative stress, fibrosis, apoptosis, and heart inflammation. In vitro studies showed that HGN reduced oxidative stress, fibrosis, apoptosis, and inflammation brought on by HG in H9C2 cells. Mechanistically, HGN inhibited these effects by blocking the RhoA-mediated MEK/ERK signalling pathway. Further studies indicated that in vivo blockade of RhoA counteracted the protective effects of HGN against DCM-related myocardial injury and its influence on cardiac inflammation, oxidative stress, fibrosis, and apoptosis. Prior investigations had demonstrated that, in models of type 2 diabetes, histological examination using HE staining revealed cardiomyocyte hypertrophy, disordered arrangement, myofibrillar fracture, and lysis, accompanied by infiltration of interstitial inflammatory cells, vacuolization, and granulation tissue formation in microvessels. Masson staining indicated a disorganised arrangement of cardiomyocytes and an increase in collagen fibres, indicative of significant fibrosis. Furthermore, oxidative stress markers, such as MDA, were significantly elevated, while antioxidant enzymes (e.g., CAT, GSH) and antioxidant capacity (e.g., FRAP) were diminished. Moreover, the levels of ROS were significantly elevated, and the number of apoptotic cardiomyocytes increased [32]. Moreover, cardiomyocytes cultured under HG conditions exhibited elevated ROS levels and an increased number of apoptotic cells [33]. In this current study, it was discovered that HGN managed to inhibit the cardiac histological abnormalities induced by STZ through HE and Masson staining experiments. To validate the effect of high glucose concentrations on H9C2 cell proliferation, this study used the CCK-8 assay to determine the optimal high glucose concentration for inducing cellular damage. Under normal conditions, the extracellular glucose concentration was 5.5 mM, serving as a physiological control [34]. In the high-glucose group, an evenly spaced concentration gradient of 45.5, 85.5, 125.5, 165.5, 205.5, 245.5, 285.5, and 325.5 mM was employed to simulate the range from mild to severe hyperglycaemia. This systematic concentration gradient ensured statistical consistency of the data while more clearly revealing the association between glucose levels and cellular responses. The glucose concentration used in the model group in this study was 165.5 mM, which was reasonable compared with the 150 mM glucose concentration used in previous studies modelling H9C2 cells. It was worth noting that a similar concentration range of 25–300 mM glucose had been used in studies investigating the effects of high glucose on cardiomyocytes [35]. In addition, HG caused H9C2 cells to experience higher levels of oxidative stress and more apoptotic cells, both of which were consistent with our results. It has been demonstrated that HGN significantly lessens cardiac damage brought on by ischemia-reperfusion (I/R) [31]. In our study, dissection of the hearts from the mice, along with measurement of serum levels of cTnT, CK, and LDH, revealed that HGN attenuated cardiac hypertrophy and reduced cTnT, CK, and LDH levels, indicating its effectiveness in alleviating myocardial injury, consistent with our findings. Previous studies had demonstrated that NF-κB activation was triggered by elevated levels of inflammatory mediators such as TNF-α, IL-6, and IL-1β. This activation directly injured cardiomyocytes and promoted fibrosis [36]. Hyperglycaemia resulted in increased reactive oxygen species (ROS) levels, triggering oxidative stress that damaged cell membranes and mitochondria, further exacerbating inflammatory responses and inducing apoptosis. Additionally, oxidative stress could activate the STAT1 pathway, leading to cardiomyocyte apoptosis [37]. Myocardial fibrosis, an important feature of cardiac pathology in DCM, was connected to inflammation, oxidative stress, and TGF-β activation. The interplay of these pathological processes ultimately contributed to the onset and progression of cardiac lesions in DCM [36]. Prior research had indicated that HGN exhibited anti-inflammatory, antioxidant, and anti-apoptotic characteristics in models of Alzheimer’s disease [38]. In our study, using both the STZ-induced DCM mouse model and the HG-induced H9C2 cell injury model, we performed immunoblotting and real-time fluorescence quantitative PCR analysis. These investigations revealed that HGN dramatically decreased the expression levels of pro-inflammatory, pro-oxidative stress, pro-fibrotic, and pro-apoptotic proteins, as well as their transcription factors, meanwhile, HGN enhanced the expression of anti-oxidative stress and anti-apoptotic proteins. As a result, in agreement with earlier studies, our findings confirmed that HGN efficiently alleviated DCM-induced cardiac inflammation, oxidative stress, fibrosis, and apoptosis. Similarly, HGN mitigated HG-induced inflammation, oxidative stress, fibrosis, and apoptosis in H9C2 cells. RhoA inhibition had been shown to effectively suppress inflammation, oxidative stress, fibrosis, and apoptosis in models of myocardial infarction (MI) and diabetic cardiomyopathy (DCM) [13, 27]. Previous research had also shown that MEK/ERK pathway activation was correlated with inflammation, oxidative stress, and apoptotic responses. For example, in rheumatoid arthritis models, activation of the MEK/ERK signalling pathway caused excessive production of inflammatory cytokines, exacerbating joint inflammation and tissue damage [39]. In liver fibrosis models, this pathway’s activation amplified the release of inflammatory cytokines, driving up the synthesis of ECM components such as collagen and worsening liver fibrosis [40]. The MEK/ERK pathway was activated due to oxidative stress, leading to neuronal damage. In Parkinson’s disease models, it increased neuronal death in response to neurotoxic damage from MPP⁺ [41]. The above research findings indicated that activation of the MEK/ERK signalling pathway could promote inflammation, fibrosis, oxidative stress, and apoptosis. To investigate the relationship between HGN, RhoA, and the MEK/ERK pathway, we transfected H9C2 cells with a RhoA overexpression plasmid (PLV3-CMV-RHOA(mouse)-3×HA-puro). Immunoblotting experiments showed that HGN treatment reduced the expression of pro-inflammatory, pro-oxidative stress, pro-fibrotic, and pro-apoptotic proteins induced by HG, while increasing the expression of antioxidant and anti-apoptotic proteins. However, RhoA overexpression reversed these effects, indicating that HGN inhibits inflammation, oxidative stress, fibrosis, and apoptosis in H9C2 cells via RhoA. Further experiments with RhoA overexpression plasmid transfection revealed that HGN treatment mitigated HG-induced activation of the MEK/ERK pathway, an effect counteracted by RhoA overexpression. This shows that HGN suppresses cardiomyocyte inflammation, oxidative stress, fibrosis, and apoptosis via regulating the MEK/ERK pathway via RhoA. Fasudil hydrochloride was a well-known RhoA inhibitor that had shown strong therapeutic potential across multiple disease models. In models of cerebral ischaemia/reperfusion injury, Fasudil hydrochloride had been shown to promote recovery of neurological function and inhibit RhoA protein expression [42]. In models of cardiac ischaemia/reperfusion injury, Fasudil hydrochloride reduced serum LDH and CK levels, implying that cardiomyocytes were less damaged. Furthermore, echocardiographic investigations showed that Fasudil hydrochloride improved heart function in DCM animals. This was indicated by large decreases in IVSD, left LVPWd, LVIDs, LVIDd, and IVSs, as well as an increase in EF and FS [43]. In the current study, ELISA and echocardiographic experiments demonstrated that HGN administration significantly reduced serum levels of cTnT, CK, and LDH in DCM mice. Moreover, the echocardiographic findings showed that the expression levels of IVSD, LVPWd, LVIDs, LVIDd, and IVSs were notably diminished, whereas EF and FS were notably elevated. This was significantly reversed by STZ + Fasudil hydrochloride + HGN, revealing that Fasudil hydrochloride abolished HGN’s preventive effect against myocardial damage in DCM mice. Fasudil hydrochloride had been reported to inhibit inflammation and oxidative stress by suppressing RhoA in a pulmonary microvascular endothelial cell (PMVEC) dysfunction model [44]. It had also been shown to inhibit fibrosis and apoptosis by suppressing RhoA in models of type 2 diabetic cardiomyopathy [45]. In this investigation, the administration of HGN dramatically decreased the expression levels of pro-inflammatory, pro-oxidative-stress, pro-fibrotic, and pro-apoptotic mRNAs, according to real-time fluorescence quantitative PCR and immunoblotting tests. After administering Fasudil hydrochloride, these effects were markedly reversed, suggesting that the therapeutic effects of HGN on oxidative stress, fibrosis, apoptosis, and cardiac inflammation in DCM mice were removed. As a RhoA inhibitor, Fazudil should theoretically have mitigated diabetic cardiomyopathy damage by suppressing RhoA. However, in the STZ + Fazudil group, we observed that relevant disease-related variables did not decrease but instead increased. This may have occurred because Fazudil’s potent inhibition of RhoA excessively suppressed its normal physiological functions, triggering adverse effects that diminished or negated therapeutic benefits. Additionally, HGN also reduced disease-related variables by inhibiting RhoA. When Fazudil and HGN had been co-administered, Fazudil’s RhoA inhibition may have interfered with HGN’s mechanism of action. Given Fazudil’s already potent RhoA inhibition, HGN’s additional suppression could have led to excessive RhoA deactivation, exacerbating disease-related variables. This dual inhibition may have disrupted RhoA’s physiological functions, thereby intensifying diabetic cardiomyopathy damage. Although our Research Results Suggested that HGN Might Have Exerted its Protective Effects Through the RhoA/MEK/ERK Signalling Pathway, the Direct Interaction between HGN and RhoA Remained Speculative at that stage. Future Studies Were Needed To Further Validate this hypothesis, Such as Through in Vitro Experiments and Molecular Biology Techniques To Directly Detect the Interaction between HGN and RhoA. In the DCM model, Various Natural Products Had Been Tested for their Potential To Mitigate the Damage Caused by Diabetic cardiomyopathy. For example, Dihydroquercetin (DHM) Had Been Shown To Exert Protective Effects Through the PI3K-Akt Signalling Pathway and the MAPK Signalling Pathway [46].Compared To these Natural Products, HGN’s Unique Mechanism of Action Via the RhoA/MEK/ERK Signalling Pathway Had Demonstrated Significant Protective Effects, Which Might Have Provided New Therapeutic Strategies for DCM; this Study Had Certain limitations, as Follows: First, the STZ dose used in this study (50 mg/kg once daily for 5 days, followed by 100 mg/kg) was closer to that of type 1 diabetes rather than type 2 diabetes. Second, translating the mouse model to a human DCM model presented challenges related to species differences, disease progression rates, and treatment responses. Third, the potential alternative effects of HGN, particularly its impact on β-adrenergic receptor activity, required further investigation. Finally, this study included only male mice, whereas female mice exhibited higher resistance to STZ. Future research plans included validating the observed phenomena in female mice to assess the impact of gender differences on treatment efficacy. Conclusion In conclusion, the findings of the present study showed that by focusing on RhoA inhibition, HGN could effectively reduce cardiac inflammation, oxidative stress, fibrosis, and apoptosis. This discovery established a strong foundation for the use of HGN as a potential therapeutic agent for DCM, in addition to offering a fresh viewpoint and a theoretical underpinning for the investigation of the molecular mechanism of DCM. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 (PDF 1.22 MB) Supplementary Material 1 (PDF 1.22 MB)